左心室壁のストレスとTAVRとMitraClip後の心臓の改造の関係
Stavroula Papapostolou1, John Shapland Kearns2, Benedict Costello3
1Alfred Health, Melbourne, Victoria, Australia.
Open heart
|September 1, 2025
まとめ
左心室壁のストレス (LVWS) は,弁の介入後の回復を予測します. MitraClipの患者で発症した静脈動脈動脈動脈動脈動脈動脈動脈動脈動脈動脈動脈動脈動脈動脈動脈動脈動脈動脈動脈動脈動脈動脈動脈動脈動脈動脈動脈動脈動脈動脈動脈動脈動脈動脈動脈動脈動脈動脈
科学分野:
- 心臓病科
- 心血管イメージング
- 介入心臓科
背景:
- 構造的介入後の心臓の改造に対する左心房壁ストレス (LVWS) の影響は十分に理解されていません.
- この研究では,トランスキャテーター大動脈弁置換 (TAVR) とMitraClip (MC) の6ヶ月後のLVWSと心臓の改造の関係を調査しています.
研究 の 目的:
- TAVRとMCの手続きの6ヶ月後に,ベースラインのLVWSと心臓リモデリングの関連性を調べる.
- 介入後の左心室 (LV) の回復と機能的結果を予測できるかどうかを判断する.
主な方法:
- LVWSは,重度の大動脈狭窄症 (AS) を有する40人の患者と,TAVRまたはMC前後の重度のミトラル吐症 (MR) を有する11人の患者で,侵襲性血液動力学および心筋MRI (CMR) を用いて計算された.
- 機能能力 (6分歩行テスト) と心臓の構造/機能 (エコーカルディオグラフィー,CMR) は,処置前と処置後6ヶ月で評価された.
主要な成果:
- TAVRとMCの両方が機能能力と心臓の改造を改善し,LVの質量または体積の減少においてグループ間の有意な違いはありませんでした.
- MCコホートにおけるベースライン流動性LVWS (D-LVWS) とTAVRコホートにおけるシストリックLVWS (S-LVWS) は,フォローアップ時により大きなLV終末流動体積とより低いエジェクション分数を予測した.
結論:
- ベースラインのD-LVWS (MC) とS-LVWS (TAVR) の上昇は,介入後のLV再構成と機能の低下と関連しています.
- LVWSはLV回復の予測として機能し,潜在的に介入のタイミングを導き,結果を最適化することができます.
さらに関連する動画
関連する概念動画
Mitral Regurgitation I: Introduction
55
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
55
Mitral Stenosis I: Introduction
34
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
34
Heart Failure II: Pathophysiology
37
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
37
Aortic Regurgitation III: Medical Management
42
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
42
Mitral Stenosis II: Clinical features and Diagnostic Tests
37
Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
37
Mitral Regurgitation III: Medical Management
28
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
28


